MAP2K1 and cancer: In co-culture experiments with patient-derived, autologous anti-tumor T cells, pretreatment with MEK inhibitor enhanced cancer cell killing by T cells relative to controls treated with drug alone, except in tumor organoids harboring the MAP2K1 S194P drug addiction variant (Extended Data Fig. 9e).